Medicina, Vol. 43. No. 2., 2007.
Pregledni rad
TREATMENT OF HEPATITIS C
Davor Štimac
; Zavod za gastroenterologiju, KBC Rijeka, Rijeka, Hrvatska
Jelena Luzer
; Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Sandra Milić
; Zavod za gastroenterologiju, KBC Rijeka, Rijeka, Hrvatska
Sažetak
SUMMARY
It is estimated that the number of hepatitis C virus (HCV) infected patients all round the world amounts to 170 million persons and it is likely to expect that the disease progression from acute to chronic ranges between 55% – 85%. The paper sets out the present knowledge on hepatitis C therapy, compares and contrasts the existing treatment methods, points at the disease side
effects and offers an insight into a future therapy trends. Nowadays, the standard HCV infection is cured by pegylated interferon and ribavirin within 24 – 48 weeks, depending on the genotype and viral response. Some special categories of patients require modified therapy. In future it is assumed that a number of new medicines, such as specific inhibitors and particularly vaccines are going to be developed thus enabling a more efficient treatment of HCV infected patients.
Ključne riječi
hepatitis C virus (HCV); pegylated interferon; ribavirin; side effects
Hrčak ID:
22567
URI
Datum izdavanja:
25.6.2007.
Posjeta: 2.785 *